Abbisko Cayman Limited
和譽開曼有限責任公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2256)

VOLUNTARY ANNOUNCEMENT ABBISKO THERAPEUTICS PRESENTED RESULTS ON MODEL-INFORMED DOSE SELECTION FOR PIMICOTINIB AT ACOP 2024

Abbisko Cayman Limited (the "**Company**", together with its subsidiaries, the "**Group**") hereby informs the shareholders and potential investors of the Company of the attached press release that Abbisko Therapeutics Co., Ltd. ("**Abbisko Therapeutics**"), a subsidiary of the Company, presented model-informed dose selection results for its self-discovered, orally available, highly selective, and potent small-molecule CSF-1R inhibitor, pimicotinib (ABSK021), for the treatment of Tenosynovial Giant Cell Tumour ("**TGCT**") at the American Conference on Pharmacometrics 2024 ("**ACoP 2024**"). The study integrated drug pharmacokinetics, safety, and efficacy data to guide model-informed dose selection. These results support 50 mg QD as the recommended dose of pimicotinib for the global development and treatment of TGCT.

This is a voluntary announcement made by the Company. The Group cannot guarantee that ABSK021 will ultimately be successfully marketed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Abbisko Cayman Limited
Dr. Xu Yao-Chang
Chairman

Shanghai, November 13, 2024

As at the date of this announcement, the board of directors of the Company comprises Dr. Xu Yao-Chang, Dr. Yu Hongping and Dr. Chen Zhui as executive directors; Ms. Tang Yanmin as a non-executive director; and Dr. Sun Piaoyang, Mr. Sun Hongbin and Mr. Wang Lei as independent non-executive directors.

ACoP 2024 — Abbisko Therapeutics presented results on model-informed dose selection for pimicotinib (ABSK021)

On November 13, 2024, Abbisko Therapeutics Co., Ltd. ("**Abbisko Therapeutics**") announced that, Abbisko Therapeutics presented model-informed dose selection results for its self-discovered, orally available, highly selective, and potent small-molecule CSF-1R inhibitor, pimicotinib (ABSK021), for the treatment of Tenosynovial Giant Cell Tumour ("**TGCT**") at the American Conference on Pharmacometrics 2024 ("**ACoP 2024**"). The study integrated drug pharmacokinetics, safety, and efficacy data to guide model-informed dose selection. **These results support 50 mg QD as the recommended dose of pimicotinib for the global development and treatment of TGCT**.

Key data points from the poster presented by Abbisko Therapeutics at this ACoP 2024 include:

Poster number：M-082

Title: Integration of Pharmacokinetics, Safety, and Efficacy into Model-informed Dose Selection for Pimicotinib

Objectives:

Pimicotinib, an oral, highly potent and selective small-molecule antagonist of CSF-1R with minimum inhibition of c-Kit and PDGFR, is currently being developed for patients with TGCT, a rare type of locally aggressive neoplasm primarily caused by the overexpression of the CSF-1 gene[1]. The objective of this analysis was to develop a population PK (popPK) model and concurrently identify intrinsic/extrinsic factors that significantly influence pimicotinib's PK profile. Additionally, an exposure-response (E-R) analysis was performed to depict the relationship between pimicotinib exposure and efficacy/safety endpoints to support the selection of appropriate doses in subsequent clinical development in patients with TGCT.

Conclusions:

The study characterized pimicotinib popPK and E-R relationships and their association with efficacy and safety. These models were used to identify optimal dose selection for pimicotinib, **supporting 50 mg QD as the recommended dose of pimicotinib for the global development and treatment of TGCT.**

Reference：

1. Cannarile MA, et al. J Immunother Cancer. 2017; 5(1):53.

About Abbisko Therapeutics

Founded in April 2016, Abbisko Therapeutics Co., Ltd., a subsidiary of Abbisko Cayman Limited (Stock Code on the Hong Kong Stock Exchange: 2256.HK), is an oncology-focused biopharmaceutical company founded in Shanghai, dedicated to the discovery and development of innovative medicines that treat unmet medical needs in China and globally. The Company was established by a group of seasoned drug hunters with rich R&D and managerial expertise from top multinational pharmaceutical companies. Since its founding, Abbisko Therapeutics has built an extensive pipeline of 16 innovative small molecule programs focused on precision oncology and immuno-oncology.

Please visit www.abbisko.com for more information.

Forward-Looking Statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.